These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35943737)

  • 1. Evaluation of tolerability and efficacy of a topical emulgel containing nanoliposomal ruxolitinib phosphate in the treatment of mild atopic dermatitis: a before-after single group pilot study.
    Naeimifar A; Ahmad Nasrollahi S; Samadi A; Aryanian Z; Akbari Javar H; Rouini M; Nassiri Kashani M; Firooz A
    J Dermatolog Treat; 2022 Dec; 33(8):3160-3164. PubMed ID: 35943737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis.
    Hoy SM
    Am J Clin Dermatol; 2023 Jan; 24(1):143-151. PubMed ID: 36538235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ruxolitinib cream for the short-term treatment of mild-moderate atopic dermatitis.
    Krajewski PK; Szepietowski JC
    Expert Rev Clin Immunol; 2023 Apr; 19(4):349-356. PubMed ID: 36542765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of linoleic acid-containing water-in-oil emulsion with urea-containing water-in-oil emulsion in the treatment of atopic dermatitis: a randomized clinical trial.
    Nasrollahi SA; Ayatollahi A; Yazdanparast T; Samadi A; Hosseini H; Shamsipour M; Akhlaghi AA; Yadangi S; Abels C; Firooz A
    Clin Cosmet Investig Dermatol; 2018; 11():21-28. PubMed ID: 29379309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acceptability and efficacy of an emollient containing ceramide-precursor lipids and moisturizing factors for atopic dermatitis in pediatric patients.
    Hon KL; Pong NH; Wang SS; Lee VW; Luk NM; Leung TF
    Drugs R D; 2013 Mar; 13(1):37-42. PubMed ID: 23456759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of an Emulgel for the Effective Treatment of Atopic Dermatitis: Biocompatibility and Clinical Investigation.
    Gómez-Farto A; Jiménez-Escobar AL; Pérez-González N; Castán H; Clares B; Arias-Santiago S; Montero-Vílchez T
    Gels; 2024 May; 10(6):. PubMed ID: 38920917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of Safety, Efficacy, and Patient Counseling for Ruxolitinib in Treating Atopic Dermatitis.
    Mancuso-Stewart E; Rodger J; Zirwas M
    Skinmed; 2023; 21(1):40-43. PubMed ID: 36987827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of topical virgin coconut oil on SCORAD index, transepidermal water loss, and skin capacitance in mild to moderate pediatric atopic dermatitis: a randomized, double-blind, clinical trial.
    Evangelista MT; Abad-Casintahan F; Lopez-Villafuerte L
    Int J Dermatol; 2014 Jan; 53(1):100-8. PubMed ID: 24320105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Placebo-controlled, double-blind, randomized, prospective study of a glycerol-based emollient on eczematous skin in atopic dermatitis: biophysical and clinical evaluation.
    Breternitz M; Kowatzki D; Langenauer M; Elsner P; Fluhr JW
    Skin Pharmacol Physiol; 2008; 21(1):39-45. PubMed ID: 18025807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Ruxolitinib Cream on Work Productivity and Activity Impairment and Associated Indirect Costs in Patients with Atopic Dermatitis: Pooled Results From Two Phase III Studies.
    Bloudek L; Eichenfield LF; Silverberg JI; Joish VN; Lofland JH; Sun K; Augustin M; Migliaccio-Walle K; Sullivan SD
    Am J Clin Dermatol; 2023 Jan; 24(1):109-117. PubMed ID: 36264430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis.
    Bissonnette R; Call RS; Raoof T; Zhu Z; Yeleswaram S; Gong X; Lee M
    Am J Clin Dermatol; 2022 May; 23(3):355-364. PubMed ID: 35368221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies.
    Papp K; Szepietowski JC; Kircik L; Toth D; Eichenfield LF; Leung DYM; Forman SB; Venturanza ME; Sun K; Kuligowski ME; Simpson EL
    J Am Acad Dermatol; 2021 Oct; 85(4):863-872. PubMed ID: 33957195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity.
    Chamlin SL; Kao J; Frieden IJ; Sheu MY; Fowler AJ; Fluhr JW; Williams ML; Elias PM
    J Am Acad Dermatol; 2002 Aug; 47(2):198-208. PubMed ID: 12140465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream.
    Kim BS; Howell MD; Sun K; Papp K; Nasir A; Kuligowski ME;
    J Allergy Clin Immunol; 2020 Feb; 145(2):572-582. PubMed ID: 31629805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ruxolitinib Cream Has Dual Efficacy on Pruritus and Inflammation in Experimental Dermatitis.
    Scuron MD; Fay BL; Connell AJ; Peel MT; Smith PA
    Front Immunol; 2020; 11():620098. PubMed ID: 33658996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of autophagy-enhancing peptide in moisturizer on atopic dermatitis: a randomized controlled trial.
    Kwon SH; Lim CJ; Jung J; Kim HJ; Park K; Shin JW; Huh CH; Park KC; Na JI
    J Dermatolog Treat; 2019 Sep; 30(6):558-564. PubMed ID: 30427231
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and acceptability of a new topical skin lotion of sodium cromoglicate (Altoderm) in atopic dermatitis in children aged 2-12 years: a double-blind, randomized, placebo-controlled trial.
    Stainer R; Matthews S; Arshad SH; McDonald S; Robinson J; Schapira C; Foote KD; Baird-Snell M; Gregory T; Pollock I; Stevens MT; Edwards AM
    Br J Dermatol; 2005 Feb; 152(2):334-41. PubMed ID: 15727648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Off-label Studies on the Use of Ruxolitinib in Dermatology.
    Tegtmeyer K; Ravi M; Zhao J; Maloney NJ; Lio PA
    Dermatitis; 2021 May-Jun 01; 32(3):164-172. PubMed ID: 33443378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical Application of JAK1/JAK2 Inhibitor Momelotinib Exhibits Significant Anti-Inflammatory Responses in DNCB-Induced Atopic Dermatitis Model Mice.
    Jin W; Huang W; Chen L; Jin M; Wang Q; Gao Z; Jin Z
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Children with atopic dermatitis show increased activity of β-glucocerebrosidase and stratum corneum levels of glucosylcholesterol that are strongly related to the local cytokine milieu.
    Kezic S; McAleer MA; Jakasa I; Goorden SMI; der Vlugt KG; Beers-Stet FS; Meijer J; Roelofsen J; Nieman MM; van Kuilenburg ABP; Irvine AD
    Br J Dermatol; 2022 Jun; 186(6):988-996. PubMed ID: 34993951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.